SLNO - Company ID 0001484565
SOLENO THERAPEUTICS INC trades as SLNO and has a market capitalization of $2.76 B, making it the #1903 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $190.41M, up 13024.2% from the prior year and net income of $20.89M. This page tracks SOLENO THERAPEUTICS INC through 1,109 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 12 fiscal years SOLENO THERAPEUTICS INC's revenue grew from $3.00M to $190.41M, a compound annual growth rate of 41.3%.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| POS AM | - | 2026-05-21 |
| AW | - | 2026-05-21 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio | Soleno Therapeutics Inc.
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer | Soleno Therapeutics Inc.
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR | Soleno Therapeutics Inc.
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, www.soleno.life .
Soleno Therapeutics to Participate in Upcoming Conferences | Soleno Therapeutics Inc.
The largest companies sharing SOLENO THERAPEUTICS INC's SEC industry classification (pharmaceutical preparations).
SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of $2.76 B as of 2026-07-09, ranking #1903 among US-listed companies.
SOLENO THERAPEUTICS INC reported revenue of $190.41M for fiscal year 2025, an increase of 13024.2% year over year.
Yes. SOLENO THERAPEUTICS INC reported net income of $20.89M in its latest fiscal year.